Industry: Cannabis Biotech
Cannabis biotech funding
Investors in cannabinoid medicine pay for controlled trial data and a drug that can get through FDA review and DEA rules. Waveup turns your science, regulatory plan and likely buyers into a case they can test.
- Investor lists and market data on cannabinoid medicines
- Decks and models built on trial readouts, DEA steps and licensing
- Waveup prepares investor materials for cannabis biotech companies: $3B+ raised for 600+ startups since 2014
In short
What is cannabis biotech funding?
Cannabis biotech funding is money raised by companies turning cannabinoids into prescription drugs. The molecules are extracted from the plant, made by chemical synthesis or brewed by engineered microbes. The money comes from life sciences VCs, research grants and drugmakers that license or buy drugs. The field's one plant-derived approved drug, Epidiolex, passed $1 billion in sales in 2025.
- Who it's for
- Cannabinoid drug developers and makers of synthetic or biosynthetic cannabinoids, pre-seed to Series D+
- What we build
- Investor deck, financial model, valuation, investor list, data room
- Prices
- Deck from $6,000, model from $3,000. Flat fees
- Track record
- $3B+ raised for 600+ startups since 2014
Market data checked on 6 November 2026. Sources are under each section.
Do investors still back cannabinoid drugs in 2026?
Yes, when a developer has controlled trial data and a clear route through the FDA. Recent trial misses have made investors stricter about both.
The opportunity
Approved cannabinoid drugs sell, and US research rules are easing.
- Drugmakers have bought cannabinoid developers, from Epidiolex's maker to a CB1 blocker startup
- A 2026 DEA rule lets registered researchers use products from state-licensed sources
- Drugs aimed at the body's own cannabinoid system have reached Phase 2, such as Synendos's anxiety candidate
The problem
Late-stage trials can still fail. Harmony's Phase 3 study of a CBD gel in 215 patients missed its main goal in September 2025.
Market size
How big is the market for cannabinoid medicines?
Epidiolex, the only FDA-approved drug derived from cannabis, had net sales of $1.06B in 2025. These four trends set the terms for newcomers:
- Steady demand: Epidiolex net sales reached $837M in the first nine months of 2026, up on a year earlier
- New forms: the FDA's target date for a decision on Jazz's cannabidiol capsule is 16 April 2027
- Rescheduling: since 28 April 2026, marijuana in an FDA-approved drug sits in Schedule III, not Schedule I
- Research policy: a December 2025 executive order calls for more medical marijuana and CBD research
Venture capital
Who pays for cannabinoid drug development now?
Venture totals for cannabinoid drug developers aren't published anywhere we could find, so the chart tracks NIH research money. Private rounds are rare, and drugmakers tend to step in once a drug has human data.
total price Jazz agreed in 2021 for GW Pharmaceuticals, the maker of Epidiolex
agreed by Novo Nordisk in 2023 for Inversago, a CB1 blocker developer, tied to milestones
Series A for Synendos in 2020, co-led by Kurma Partners and Sunstone Life Science Ventures
Who invests in cannabis biotech startups?
Life sciences VCs that backed a cannabinoid drug developer, drugmakers that bought cannabinoid medicines, and US research money. For more biotech investors, see our life sciences VC list.
Investor database
Biotech investors in our database
The funds with the most biotech investments. Pick a stage, or open a fund for its cheque sizes.
Top 5 by biotech investments
Investments by industry
- Healthtech & Wellness47%
- Biotech26%
- Pharma20%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- $100K–$500K$500K–$1M$1M–$3M$3M–$10M
- Based in
- Chicago, United States
- Invests in
- USA
502 investments in total, 23 tagged Biotech.Open the full fund profile
Investments by industry
- Healthtech & Wellness41%
- Biotech36%
- Pharma18%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- $0–$100K$100K–$500K$500K–$1M$1M–$3M$3M–$10M
- Based in
- Boston, United States
- Invests in
- USA
141 investments in total, 22 tagged Biotech.Open the full fund profile
Investments by industry
- Healthtech & Wellness38%
- Biotech33%
- Pharma17%
- Rounds
- SeedSeries ASeries C+
- Average cheque
- $0–$100K$100K–$500K$500K–$1M$1M–$3M$3M–$10M
- Based in
- San Francisco, United States
- Invests in
- USA
196 investments in total, 20 tagged Biotech.Open the full fund profile
Investments by industry
- Healthtech & Wellness44%
- Biotech27%
- Pharma15%
- Rounds
- Series ASeries BSeries C+
- Average cheque
- Not listed
- Based in
- Boston, United States
439 investments in total, 18 tagged Biotech.Open the full fund profile
Investments by industry
- Healthtech & Wellness46%
- Biotech25%
- Pharma16%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- Not listed
- Based in
- United States
- Invests in
- Israel, Europe, USA +1
231 investments in total, 17 tagged Biotech.Open the full fund profile
From our investor database.
What makes cannabinoid drug developers hard to fund?
In our Fundraising 2025 study, 56 VCs named their top reasons to pass. Revenue growth, unit economics, burn and missed milestones came first, then defensibility and crowded categories. In cannabinoid medicine, the missed milestone is usually a trial, and defensibility means what you can patent.
Trials that miss
Skye's CB1 antibody missed its main goal when given alone in a 2025 trial. Skye paused the drug in Q2 2026 and agreed to combine with Redx, a UK fibrosis drug developer.
What investors ask
- How does your drug do next to what patients already take?
What your deck shows
- Trials that test your drug on top of, or against, current care
- Cash for a second trial if the first one misses
Two regulators, one timeline
A US trial can start 30 days after an IND filing unless the FDA acts sooner. Studies of Schedule I drugs also need a DEA registration for each site.
What investors ask
- Which DEA steps sit between your IND and the first patient dosed?
What your deck shows
- FDA and DEA steps on one dated timeline
- A licensed source of research-grade drug
Data you can file
Universities and hospitals run much of the research. Only 190 of the 542 cannabidiol studies on ClinicalTrials.gov list industry as a funder.
What investors ask
- Which of your results come from controlled trials you can submit to the FDA?
What your deck shows
- Your own controlled data, set apart from academic studies
- Data rights agreed with every academic partner
Plant, synthetic or brewed
The DEA's April 2026 rule moved marijuana in FDA-approved drugs into Schedule III. Synthetic THC stayed in Schedule I under the same rule.
What investors ask
- Which schedule covers your molecule, before and after approval?
What your deck shows
- Counsel's view of your molecule's legal status
- A supply chain that stays compliant if rules change
How we help you raise
Flat fees agreed before we start. No success fee on advisory work.
Your science, trial plan and FDA and DEA path, told plainly.
Trial costs, readout dates and runway, month by month.
A range tested against cannabinoid and CNS drug deals.
Life sciences VCs, grant bodies and drugmakers that fit your stage.
Trial data, DEA registrations and supply records, ready to review.
For a licensing deal or a sale to a drugmaker.
Who we are
Waveup is a London-based fundraising and growth advisory, working in 60+ countries and 90+ industries. Since 2014 we have built the decks, models, CIMs and valuations behind $3B+ raised for 600+ startups. Biotech and pharma are the largest group among our 54+ deep-tech projects.
About usCannabis biotech funding FAQ
What does a cannabis biotech company do?
Which cannabinoid drugs has the FDA approved?
How do cannabis biotech startups get funding?
What do investors look for in a cannabinoid drug developer?
Is cannabis research getting easier in the US?
How much does help with a cannabis biotech raise cost?
Raising for a cannabis biotech company?
Share your molecule, how you make it and your next trial readout. We'll show you how a life sciences investor is likely to read your case.



